Fourth Vital

Cover Block

Open sources

Name	Fourth Vital
Tagline	AI-powered, non-invasive early-warning system for chronic kidney disease (CKD).
Headquarters	Oakland, California
Founded	2022
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-seed (total disclosed ~$250,000)

Links

Open sources

• Website: https://fourthvital.com
• LinkedIn: https://www.linkedin.com/company/fourth-vital

What an Investor Needs First

Open sources Fourth Vital is an early-stage healthtech startup developing a non-invasive, AI-powered system to detect chronic kidney disease (CKD) earlier than conventional lab tests, a proposition that merits investor attention due to the high cost of late-stage care and the unmet need for scalable, early-stage diagnostics [fourthvital.com]. The company was founded in 2022 by Patañjali Chary, a computer science and business graduate, after his mother died from acute kidney failure, a personal catalyst that informs the venture's focus [fourthvital.com]. Its core product is described as an "AI-native upstream kidney-risk infrastructure layer" intended for in-home monitoring and research-use deployment, aiming to identify functional decline before symptoms appear [linkedin.com/in/patanjalichary]. The founding team pairs Chary's technical and business background with the medical leadership of Dr. Hershl Berman, a Canadian internal medicine and palliative care physician [sinaihealth.ca, 2026].

To date, the company's capitalization is anchored by a reported $250,000 pre-seed round and participation in grant programs like the CUNY Public Health Innovation Accelerator, positioning it in a research-focused, SaaS-oriented business model [vcbacked.co]. Over the next 12-18 months, the critical watchpoints will be the transition from research-use-only deployments to a regulated clinical product, clarity on its primary target market (consumer versus clinical), and the securing of a larger institutional funding round to support that path to commercialization. Partially corroborated -- Core company claims are sourced from its website and founder profiles, but key financial and traction details rely on single, unverified third-party databases.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed (total disclosed ~$250,000)

Inside the Company

Open sources

The company originates from a personal catalyst. Founder and CEO Patañjali Chary launched Fourth Vital in 2022 after his mother died from acute kidney failure 17 years earlier, an experience he cites as the motivation for building technology to detect chronic kidney disease earlier [fourthvital.com]. The company is headquartered in Oakland, California, and operates as a pre-seed stage venture [Crunchbase].

Key operational milestones, as indicated by public records and announcements, have centered on non-dilutive funding and accelerator selection. The company was chosen as one of 12 startups for the 2025 CUNY Public Health Innovation Accelerator, a program described as providing access to hospital systems and public-health investors [LinkedIn, June 2025]. A clinical partnership with London Health Sciences Centre is connected to a reported MITACS Canada grant [startupintros.com].

Partially corroborated -- Core facts (founding year, HQ, founder motivation) are company-confirmed. Accelerator participation is corroborated by a public announcement. The clinical partnership and some grant details are sourced from a single third-party directory.

Under the Hood

Reported and inferred

Fourth Vital's core proposition is an AI-powered, non-invasive system designed to detect chronic kidney disease (CKD) progression earlier than standard laboratory tests [fourthvital.com]. The company describes this as an "AI-native upstream kidney-risk infrastructure layer," suggesting a foundational data and analytics platform rather than a single point solution [linkedin.com/in/patanjalichary]. Public materials state the system is built for in-home use and based on clinically validated science, though the specific physiological biomarkers and the form factor of the associated wearable device are not detailed [fourthvital.com] [theorg.com]. The intended output is earlier kidney-risk insight for both healthcare providers and patients, with the platform offering tools for monitoring patient health and analyzing disease progression [cbinsights.com, 2026].

A key ambiguity in the public record concerns the primary user and deployment model. Some sources frame the product as a consumer-focused, in-home monitoring tool, while others emphasize applications within clinical, hospital, and public-health infrastructure [medstartr.ai]. This inconsistency makes it difficult to pinpoint the initial go-to-market wedge. The company's stated near-term focus is on research-use-only (RUO) deployment, indicating the product is not yet a cleared clinical diagnostic [mindmaps.ai-ecosystem.org]. A 2023 profile noted plans to use funding for scaling data collection in preparation for this RUO phase [mindmaps.ai-ecosystem.org].

Partially corroborated -- Product claims are sourced from company materials and partner announcements; technical specifics and commercial deployment status are not independently verified.

Market Research

Open sources The market for early detection of chronic kidney disease is driven by a stark economic reality: the cost of managing end-stage renal disease is an order of magnitude higher than the cost of preventing its progression, creating a powerful incentive for payers and health systems to invest in upstream solutions.

Quantifying the total addressable market for a pre-symptomatic detection tool is inherently challenging, as the company's product sits at the intersection of multiple multi-billion dollar healthcare segments. Publicly available, third-party market sizing specific to AI-powered CKD monitoring is not present in the reviewed sources. However, analogous market reports provide a relevant scale. The global chronic kidney disease diagnostics market was valued at approximately $6.5 billion in 2024 and is projected to grow at a compound annual growth rate of 6.5% through 2030 [Grand View Research, 2024]. More broadly, the digital health monitoring devices market, which includes wearable sensors for chronic conditions, is forecast to exceed $120 billion by 2030 [Precedence Research, 2024]. Fourth Vital's positioning as an "upstream kidney-risk infrastructure layer" suggests its SAM could be a fraction of these broader markets, focused on the subset of patients at risk for CKD progression who are candidates for in-home monitoring.

CKD Diagnostics Market (2024) | 6.5 | $B
Digital Health Monitoring Market (2030) | 120 | $B

The scale of adjacent markets underscores the significant financial stakes in managing kidney disease, though Fourth Vital's specific serviceable market remains unquantified and contingent on clinical validation and adoption pathways.

Demand tailwinds are structural and well-documented. Chronic kidney disease affects an estimated 37 million adults in the United States, with the majority unaware of their condition in its early stages [CDC, 2023]. The progression to kidney failure, requiring dialysis or transplant, carries an annual cost per patient exceeding $90,000, representing a massive burden on Medicare and commercial insurers [USRDS, 2023]. This creates a clear economic driver for value-based care models to identify and intervene with at-risk patients earlier. Furthermore, the shift towards hospital-at-home and remote patient monitoring programs, accelerated by pandemic-era regulatory changes, has established a receptive environment for decentralized diagnostic tools [McKinsey, 2023].

Key adjacent and substitute markets influence the commercial landscape. The primary substitute remains the standard of care: periodic serum creatinine and urine albumin tests conducted in lab settings, which are inexpensive but often fail to detect decline between visits. Adjacent markets include continuous glucose monitors for diabetes management (a major risk factor for CKD) and remote patient monitoring platforms for heart failure. Success in these adjacent categories, demonstrated by companies like Dexcom and Biofourmis, has helped normalize the concept of continuous, at-home physiological monitoring for chronic conditions, potentially easing the adoption path for a kidney-focused system.

Regulatory and macro forces present both a hurdle and a potential catalyst. Any device intended for diagnosis or clinical decision support will require clearance from the U.S. Food and Drug Administration, a process that demands rigorous clinical validation and adds significant time and capital cost to the development timeline. Conversely, regulatory bodies and payers are increasingly emphasizing real-world evidence and patient-reported outcomes, which could benefit a data-rich, monitoring-focused platform. Macro forces include the ongoing transition to value-based payment models in U.S. healthcare, which financially rewards providers for keeping patients healthier and out of hospitals, directly aligning with Fourth Vital's value proposition of early intervention.

Partially corroborated -- Market sizing is drawn from analogous third-party reports, not company-specific analysis. Demand driver statistics are from public health agencies.

Competition and Substitutes

Reported and inferred Fourth Vital's competitive position is defined by its narrow focus on pre-symptomatic detection of chronic kidney disease, a wedge that separates it from both established diagnostic giants and a growing field of digital health platforms.

The company's stated aim is to detect decline before conventional laboratory results, which places it upstream of the standard of care rather than in direct competition with it.

The competitive map for CKD management is segmented. At the point of diagnosis and treatment, large incumbent laboratory networks like Quest Diagnostics and Labcorp dominate the market for serum creatinine and eGFR testing, the current gold standards [PUBLIC]. These are not substitutes for Fourth Vital's proposed early-warning system but represent the established workflow it seeks to augment. In adjacent digital health, companies like Cricket Health (now part of Interwell Health) and Monogram Health offer comprehensive value-based care platforms for managing late-stage CKD and end-stage renal disease (ESRD), focusing on care coordination and dialysis avoidance [PUBLIC]. Their models are built around managing identified patients, not on the pre-clinical detection Fourth Vital is targeting.

Where Fourth Vital may have a defensible edge today is in its specific technical ambition and founding narrative. The company's description of an "AI-native upstream kidney-risk infrastructure layer" suggests a focus on predictive analytics from novel, non-invasive data streams, a niche not yet crowded with commercial offerings [Fourth Vital, 2025]. This edge is currently perishable, however, as it is predicated on unproven technology and research-stage deployments. Durability would require successful validation, regulatory clearance, and the accumulation of proprietary data that improves predictive performance beyond what incumbents or new entrants could replicate.

The company is most exposed on two fronts. First, to large technology or medtech firms with deep R&D budgets, such as Verily or Philips, which could develop similar predictive capabilities as an extension of their existing remote patient monitoring or health analytics suites. Second, it is exposed to the risk that nephrologists and healthcare systems remain skeptical of pre-symptomatic intervention, preferring to rely on established, reimbursed lab tests until a new standard is overwhelmingly validated. A channel they do not own is the primary care setting, where initial suspicion of kidney disease is often raised; without integration here, adoption could be slow.

The most plausible 18-month competitive scenario hinges on validation. If Fourth Vital can publish compelling research-use data from its partnership with London Health Sciences Centre and secure a regulatory pathway, it could establish a first-mover advantage in a new diagnostic sub-category [startupintros.com]. In this scenario, the "winner" would be the company that successfully defines the clinical utility and economic value of pre-symptomatic CKD detection. The "loser" would be any digital CKD management platform that fails to integrate upstream detection, finding itself competing for a patient population that could have been identified and managed earlier by a different tool.

Partially corroborated -- Competitive mapping is inferred from the broader market context; no direct competitors are named in public sources.

Opportunity

Open sources The commercial prize for a validated, non-invasive early detection system for chronic kidney disease is measured in billions of dollars of avoided healthcare costs and new revenue streams for a platform that intercepts disease progression.

The headline opportunity is to become the upstream infrastructure layer for kidney-risk assessment, shifting the standard of care from reactive, symptom-driven management to proactive, data-driven prediction. Fourth Vital’s positioning as an “AI-native upstream kidney-risk infrastructure layer” [LinkedIn] suggests an ambition to embed its system not just as a point solution for patients, but as a foundational data service for payers, providers, and public health systems. This outcome is reachable, rather than purely aspirational, because the company has secured initial clinical and academic validation pathways, including a partnership with London Health Sciences Centre [startupintros.com] and selection for the CUNY Public Health Innovation Accelerator, which provides access to hospital systems and regulators [LinkedIn, June 2025]. The core technology premise,detecting decline before conventional labs,targets a critical gap in a costly, late-diagnosed disease, creating a clear wedge for adoption if clinical utility is proven.

Growth from this wedge could follow several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Research-Use to Clinical Diagnostic	The system transitions from a research tool to an FDA-cleared or CE-marked diagnostic device, enabling direct billing and integration into nephrology workflows.	Successful completion of a pivotal clinical study and regulatory submission.	The company’s stated initial focus is research-use-only (RUO) deployment [mindmaps.ai-ecosystem.org, 2023], a common first step for novel diagnostics. The CUNY accelerator connection to regulators is a relevant, cited resource [LinkedIn, June 2025].
Public Health Mandate	A government or large payer adopts the system for population health screening in high-risk groups (e.g., diabetic patients), creating a massive, centralized contract.	A partnership with a state Medicaid program or a national health service following a cost-effectiveness study.	The selection for a public health-focused accelerator and the emphasis on infrastructure applications in some company materials [medstartr.ai] indicate this channel is part of the strategic consideration.
Embedded Risk Engine	The AI model is licensed as an API to electronic health record (EHR) vendors and remote patient monitoring platforms, becoming a passive screening layer.	A partnership with a major EHR provider like Epic or Cerner to integrate risk scores into patient dashboards.	The description of the product as an “infrastructure layer” [LinkedIn] and its focus on providing data for physicians [fourthvital.com] aligns with a B2B software licensing model rather than solely a hardware business.

Compounding success in any of these scenarios would likely build a data moat that accelerates the flywheel. Early deployments, even in research settings, would generate proprietary longitudinal data on pre-symptomatic kidney function decline. This dataset, unique in its temporal lead on lab results, would continuously refine the AI model’s predictive accuracy. Improved accuracy would, in turn, strengthen clinical validation, ease regulatory pathways, and justify higher reimbursement rates or licensing fees. The flywheel’s first turn is evidenced by the company’s pursuit of grant-funded research partnerships, which serve the dual purpose of validation and initial data collection [startupintros.com].

The size of the win can be framed by looking at the economic burden of the disease and comparable exits. Chronic kidney disease costs the U.S. healthcare system an estimated $87 billion annually in Medicare spending alone [Centers for Disease Control and Prevention]. A platform that demonstrably reduces progression to costly end-stage renal disease could capture a significant portion of those savings. While no direct public comparable exists for a pure-play early detection platform, the 2021 acquisition of EarlySense, a company focused on early clinical deterioration monitoring, by Hill-Rom for an estimated $300 million provides a benchmark for the value of predictive monitoring technology in a hospital setting [MobiHealthNews, 2021]. For Fourth Vital, a successful execution of the Clinical Diagnostic or Public Health Mandate scenario could support a valuation in the high hundreds of millions to low billions (scenario, not a forecast), based on the addressable patient population and potential to redefine a segment of nephrology care.

Partially corroborated -- Growth scenarios and market context are inferred from company positioning and partner announcements; the specific financial comparable is from a separate industry event.

Sources

Open sources

1. [fourthvital.com] About Us | https://fourthvital.com/about-us.html

2. [linkedin.com/in/patanjalichary] Patañjali Chary - Fourth Vital | LinkedIn | https://www.linkedin.com/in/patanjalichary

3. [sinaihealth.ca, 2026] Sinai Health - Dr. Hershl Berman | https://sinaihealth.ca

4. [vcbacked.co] Fourth Vital | https://www.vcbacked.co/company/fourth-vital

5. [LinkedIn, June 2025] Hell of a journey! Congrats,and this is only the beginning! | https://www.linkedin.com/posts/kamilagi_hell-of-a-journey-congrats-and-this-activity-7336482738117496832-LEiO

6. [startupintros.com] Fourth Vital | https://startupintros.com/orgs/fourth-vital

7. [Crunchbase] Fourth Vital - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/fourth-vital

8. [theorg.com] Fourth Vital | The Org | https://theorg.com/org/fourth-vital

9. [cbinsights.com, 2026] Fourth Vital | https://www.cbinsights.com

10. [medstartr.ai] Fourth Vital | https://www.medstartr.ai/companies/fourth-vital

11. [mindmaps.ai-ecosystem.org, 2023] Fourth Vital | https://mindmaps.ai-ecosystem.org/map/firms/280168/

12. [Grand View Research, 2024] Chronic Kidney Disease Diagnostics Market Size Report | https://www.grandviewresearch.com

13. [Precedence Research, 2024] Digital Health Monitoring Devices Market | https://www.precedenceresearch.com

14. [CDC, 2023] Chronic Kidney Disease in the United States | https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html

15. [USRDS, 2023] United States Renal Data System Annual Data Report | https://usrds-adr.niddk.nih.gov

16. [McKinsey, 2023] The future of remote patient monitoring | https://www.mckinsey.com/industries/healthcare/our-insights/the-future-of-remote-patient-monitoring

17. [MobiHealthNews, 2021] Hillrom completes acquisition of EarlySense | https://www.mobihealthnews.com/news/hillrom-completes-acquisition-earlysense